OTCMKTS:BSEM BioStem Technologies (BSEM) Stock Price, News & Analysis $7.04 -3.34 (-32.14%) As of 08/15/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About BioStem Technologies Stock (OTCMKTS:BSEM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioStem Technologies alerts:Sign Up Key Stats Today's Range$5.02▼$8.1950-Day Range$7.04▼$14.3052-Week Range$5.02▼$28.26Volume510,273 shsAverage Volume32,287 shsMarket Capitalization$117.92 millionP/E Ratio6.18Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida. Read More Receive BSEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioStem Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address BSEM Stock News HeadlinesBSEM Expands MarginsAugust 15 at 6:06 PM | msn.comBioStem Technologies, Inc.: BioStem Technologies Appoints Brandon Poe as Chief Financial OfficerAugust 15 at 6:03 AM | finanznachrichten.deThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.” | Weiss Ratings (Ad)BioStem Technologies, Inc.: BioStem Technologies Reports Preliminary Second Quarter 2025 Financial ResultsAugust 15 at 6:03 AM | finanznachrichten.deBioStem Technologies, Inc. (BSEM) Q2 2025 Earnings Call TranscriptAugust 14 at 9:10 PM | seekingalpha.comBioStem Technologies Reports Preliminary Second Quarter 2025 Financial ResultsAugust 14 at 4:14 PM | globenewswire.comBioStem Technologies Appoints Brandon Poe as Chief Financial OfficerAugust 14 at 4:01 PM | globenewswire.comBioStem Technologies (BSEM) to Release Quarterly Earnings on ThursdayAugust 13, 2025 | americanbankingnews.comSee More Headlines BSEM Stock Analysis - Frequently Asked Questions How have BSEM shares performed this year? BioStem Technologies' stock was trading at $13.84 at the beginning of the year. Since then, BSEM shares have decreased by 49.1% and is now trading at $7.04. How were BioStem Technologies' earnings last quarter? BioStem Technologies, Inc. (OTCMKTS:BSEM) announced its quarterly earnings results on Monday, May, 12th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $1.25 by $1.08. The firm had revenue of $72.53 million for the quarter, compared to analysts' expectations of $101.20 million. Read the conference call transcript. How do I buy shares of BioStem Technologies? Shares of BSEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioStem Technologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioStem Technologies investors own include NVIDIA (NVDA), Tesla (TSLA), Broadcom (AVGO), Advanced Micro Devices (AMD), SoFi Technologies (SOFI) and Energy Transfer (ET). Company Calendar Last Earnings5/12/2025Today8/16/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryN/A Current SymbolOTCMKTS:BSEM Previous SymbolOTCMKTS:BSEM CIK1658678 Webwww.biostemtechnologies.com Phone954-380-8342FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio6.18 Forward P/E Ratio4.99 P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$301.83 million Price / Sales0.39 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares16,750,000Free FloatN/AMarket Cap$117.92 million OptionableN/A Beta-0.29 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:BSEM) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioStem Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioStem Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.